Accustem Sciences (ACUT) Cash & Current Investments (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Cash & Current Investments of $12207.0 for Q1 2026, down 66.45% year-over-year from $36381.0 in Q1 2025, and down 15.18% quarter-over-quarter from $14391.0 in Q3 2025.
Accustem Sciences (ACUT) Cash & Current Investments (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Cash & Current Investments for 5 consecutive years, with $12207.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 66.45% year-over-year to $12207.0; the TTM figure through Mar 2026 stood at $12207.0 (down 66.45% YoY), while the FY2024 annual figure was $5046.0, down 76.51% from the prior year.
- Cash & Current Investments retreated to $12207.0 in Q1 2026 per ACUT's latest filing, from $14391.0 in the prior quarter.
- Across five years, Cash & Current Investments topped out at $3.2 million in Q1 2022 and bottomed at $5046.0 in Q4 2024.
- Historically, Cash & Current Investments has averaged $513138.7 across 5 years, with a median of $37080.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash & Current Investments tumbled 97.07% — and 2025, when it surged 288.15%.
- Accustem Sciences' Cash & Current Investments stood at $733978.0 in 2022, then sank by 97.07% to $21481.0 in 2023, then tumbled by 76.51% to $5046.0 in 2024, then surged by 185.2% to $14391.0 in 2025, then decreased by 15.18% to $12207.0 in 2026.
- Business Quant data shows ACUT's Cash & Current Investments at $12207.0 in Q1 2026, $14391.0 in Q3 2025, and $31341.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 12,928.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,207.00 |
| Sep 30, 2025 | 14,391.00 |
| Jun 30, 2025 | 31,341.00 |
| Mar 31, 2025 | 36,381.00 |
| Dec 31, 2024 | 5,046.00 |
| Sep 30, 2024 | 37,080.00 |
| Jun 30, 2024 | 46,072.00 |
| Mar 31, 2024 | 9,373.00 |
| Dec 31, 2023 | 21,481.00 |
| Sep 30, 2023 | 71,010.00 |
| Jun 30, 2023 | 120,651.00 |
| Dec 31, 2022 | 733,978.00 |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.98 Mn |
| Mar 31, 2022 | 3.24 Mn |